CHEK2 and sarcoma: Figure 1 shows the distribution of P/LP and VUS mutations according to specific sarcoma pathology. The most frequently P/LP variants encountered were APC (n = 5, 22.7%), TP53 (n = 3, 13.6%), NF1 (n = 3, 13.6%), BRCA2 (n = 2, 9.1%), BRIP1 (n = 2, 9.1%), MUTYH (n = 2, 9.1%), and one (4.5%) patient each with BRCA1, CDKN2A, CHEK2, PALB2, NTHL. Notably, four out of the five APC P/LP mutations were increased risk allele (I1307K variant).